|
|
|
| Effect of apatinib mesylate tablets in the third-line treatment of extensive-stage small cell lung cancer |
| DU Chunjuan1, GUO Fengli2, HAN Xia1, LI Mianli1, WANG Feng1, NING Fangling1, HAO Yanzhang1, CHEN Shaoshui1, YUAN Haibin3* |
1 Oncology Department, Binzhou Medical University Hospital, Binzhou 256603, Shandong, P.R.China;
2 Breast Surgery Department, Binzhou Medical University Hospital, Binzhou 256603, Shandong, P.R.China;
3 Health Management Department, Binzhou Medical University Hospital, Binzhou 256603, Shandong, P.R.China |
|
|
|
|
Abstract Objective To evaluate the clinical effect and safety of apatinib mesylate tablets in the third-line treatment of extensive-stage small cell lung cancer (SCLC).Methods All extensive-stage SCLC patients involved in this study were admitted and treated from January 2016 to June 2018, who were randomly divided into two groups: the apatinib group who received apatinib (500 mg/day) until the disease progressed or became intolerable, and the paclitaxel group who were treated with Paclitaxel (175 mg/m2, 3 weeks). Patients were matched for sex, age, smoking history, ECOG, organ metastasis, hemoglobin, etc. Progression-free survival (PFS), overall survival (OS) and adverse effects were evaluated.Results The median PFS in the apatinib group and the paclitaxel group were 3.7 months and 1.9 months, respectively, and the median OS were 6.6 months and 3.0 months, respectively. The PFS and OS were both significantly longer in the apatinib group than in those in the paclitaxel group, P＜0.05. The adverse effects in the apatinib group such as hypertension, fatigue and elevation of transaminase were grade 1-2, and there were no grade 3 or above.Conclusion Apatinib in the third-line treatment is possible to improve the prognosis for extensive-stage SCLC patients, and there are no obvious adverse effects.
|
|
Received: 06 March 2020
|
|
|
|
|
|
[1] BUNN P A,MINNA J D,AUGUSTYN A,et al.Small cell lung cancer: Can recent advances in biology and molecular biology be translated into improved outcomes[J].Thorac Oncol,2016,11(4):453-474.[2] ROSSI A,DI MAIO M,CHIODINI P,et al.Carboplatin-or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: The COCIS meta-analysis of individual patient data[J].Clin Oncol,2012,30(14):1692-1698.
[3] STINCHCOMBE T E,GORE E M.Limited-stage small cell lung cancer: current chemoradiotherapy treatment paradigms[J].Oncologist,2010,15(2): 187-195.
[4] ASAI N,OHKUNI Y,MATSUNUMA R,et al.Efficacy and safety of amrubicin for the elderly patients with refractory relapsed small cell lung cancer as third-line chemotherapy[J].J Cancer Res Ther,2012,7(2):266-271.
[5] SARUWATARI K,UMEMURA S,NOMURA S,et al.Prognostic factor analysis in patients with small-cell lung cancer treated with third-line chemotherapy[J].Clin Lung Cancer,2016,17(6): 581-587.
[6] LU H,JIANG Z.Advances in antibody therapeutics targeting small-cell lung cancer[J].Adv Clin Exp Med,2018,27(9): 1317-1323.
[7] HOM L,MANSFIELD A S,SZCAESNA A,et al.First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer[J].N Engl J Med,2018,379(6):2220-2229.
[8] SPIGEL D R,TOWNLEY P M,WATERHOUSE D M,et al.Randomized phase study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial[J].J Clin Oncol,2011,29(16):2215-2222.
[9] CHENG Y,WANG Q M,LI K,et al.Anlotinib as third-line or further-line treatment in relapsed SCLC: a multicentre,randomized,double-blind phase 2 trial[EB/OL].The WCLC,2018.
[10] 朱丹,赵宏伟,赵健琦,等.肿瘤分子靶向药物阿帕替尼的临床研究进展[J].中国医院药学杂志,2017,37(2):194-198. |
| [1] |
YANG Menglu, SUN Weimei, LI Xiaohua, LI Jianchang. Research on rating of prognostic factors in children immune thrombocytopenia[J]. 滨州医学院学报, 2020, 43(4): 260-263. |
| [2] |
MA Dejing, LU Feng, ZHANG Hu, DONG Jingmin, MA Mimi. Correlation analysis among parameters of IVIM-DWI model, prognostic factors and molecular subtypes of breast cancer[J]. 滨州医学院学报, 2019, 42(5): 349-352. |
| [3] |
GE Fengmei, YAN Xiuqing, WANG Fangfang, WANG Xinyun, SHI Fang, WANG Xuebin. Analysis of the characteristics of hospitalized patients with systemic lupus erythematosus in the Yellow River Delta[J]. 滨州医学院学报, 2018, 41(5): 351-353. |
| [4] |
. [J]. 滨州医学院学报, 2018, 41(5): 388-390. |
| [5] |
LIU Li, SUN Bin, HAN Haixia, MA Shipeng, WANG Ruixia, QIU Jianqing. The value of initial clinical data to evaluate the prognosis of patients with acute paraquat poisoning[J]. 滨州医学院学报, 2018, 41(2): 101-104. |
| [6] |
JIAN Jinbo, ZHANG Luyan, YU Zeshun, NING Fangling. Clinical significance of pleural effusion LDH in patients with lung adenocarcinoma complicated with malignant pleural effusion[J]. 滨州医学院学报, 2017, 40(2): 100-102. |
|
|
|
|
